Experimental drug combination triggers tumor responses in advanced pancreatic cancer trial

In short
- Tango Therapeutics reported the trial results.
- Tumor responses occurred in 82% of patients with a certain type of advanced pancreatic cancer.
- The combination is experimental and remains in trials.
Why the Good News Desk likes this one
The result comes from a trial of an experimental drug combination, so it is not yet a standard treatment. The report describes tumor responses, not survival or side effects, which the source does not cover. Whether the responses last and help patients live longer is still open.
Advertisement
From STAT
An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.
Ask this story
More like this
Advertisement

